Rapid adoption of live cell kinetics and real time biology in the design and validation of adoptive T cell strategies

Adoptive cell therapies have come of age, establishing living cells as a powerful therapeutic modality in terms of specificity, durability and adaptability. Agilent Seahorse technology is enabling the shift to real-time quantification of immune cell function, opening a new window on controlling immune cell fate and outcomes. Several translational research studies have demonstrated that altering metabolic behavior can direct immune responses and outcomes. Move beyond analyzing what your cells are, and reveal a clearer picture of what they do in order to harness their therapeutic potential..

What you will learn during the eSeminar:

  • How to measure immune cell fate and function using Agilent Seahorse XF technology
  • How metabolic reprogramming can dramatically alter the phenotype and function of immune cells
  • Review studies that utilize Agilent Seahorse XF technology to design and validate immunotherapy approaches

For Research Use Only.  Not for use in diagnostic procedures.

Tuesday, December 11, 2018
8:00 PDT (Los Angeles)
11:00 EDT (New York)
16:00 BST (London)

Available On Demand after December 11
All registrants will be notified when available

Presented by:

David Ferrick, Ph.D
Senior Director
Cell Analysis Division
Agilent Technologies

Learn more about Agilent Seahorse XF Technology